1[1]Marino MR, Langebacher KM, Raymond RH, et al. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis[J]. J Clin Pharmacol,1998,38(4):347.
2[2]Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin Ⅱ-receptor blockers, irbesartan and losartan[J]. Clin Ther,1998,20(3):398.
3[3]Kenneth KT, Thomas L, William E, et al. For the irbesartan/losartan study investigators[J]. Am J Hypertens, 1998,11:445.
4[4]Burrell LM, Johnston CI. Angiotensin Ⅱ-receptor antagonists, potential in elderly patients with cardiovascular disease[J]. Drugs Aging,1997,10(6):421.
5陈修等.心血管药理学[M]人民卫生出版社,1997.
6M. R. Goldberg,M. W. Lo,T. E. Bradstreet,M. A. Ritter,P. H?gland. Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist[J] 1995,European Journal of Clinical Pharmacology(1-2):115～119
